Editorial
Copyright ©2011 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Hypertens. Dec 23, 2011; 1(1): 3-6
Published online Dec 23, 2011. doi: 10.5494/wjh.v1.i1.3
Manidipine: A different dihydropyridine
Christos V Rizos, Moses S Elisaf
Christos V Rizos, Moses S Elisaf, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina 45110, Greece
Author contributions: Rizos CV and Elisaf MS contributed equally to this paper
Correspondence to: Moses Elisaf, MD, FASA, FRSH, Professor, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina 45110, Greece. egepi@cc.uoi.gr
Telephone: +30-26510-07509 Fax: +30-26510-07016
Received: August 20, 2011
Revised: October 20, 2011
Accepted: December 16, 2011
Published online: December 23, 2011

Abstract

Blood pressure (BP) plays an important role in the development and progression of cardiovascular disease. Moreover, hypertensive patients often have additional cardiovascular risk factors. Despite the abundance of antihypertensive drug categories, satisfactory BP regulation is often difficult to achieve. A major cause of this difficulty to properly manage BP is the less than optimal adherence of subjects to treatment. This is often due to the various adverse effects of the antihypertensive drugs. Calcium channel blockers (CCB) have an established efficacy for reducing BP. However, their side effect of peripheral edema is often a cause for the discontinuation of treatment. Manidipine holds some unique properties differentiating it from the rest of the CCB class. It has a better safety profile with a lower incidence of peripheral edema. Moreover, there are indications that manidipine holds additional beneficial attributes, such as improvement of renal function and decrease of insulin resistance.

Key Words: Manidipine, Hypertension, Calcium channel blockers, Peripheral edema, Renal function, Insulin resistance



INTRODUCTION

Hypertension is one of the key factors for cardiovascular disease (CVD) development and progression. The prevalence of hypertensive patients is continuously increasing[1]. Hypertensive subjects often have additional CVD risk factors, such as hyperlipidemia, impaired glucose metabolism and renal impairment, leading to an increased rate of CVD morbidity and mortality[2]. Therefore, a comprehensive management of both hypertension as well as concomitant CVD risk factors is critical when treating hypertensive patients.

There are various categories of antihypertensive drugs. However, despite the plethora of blood pressure (BP) lowering agents, satisfactory control of hypertension is often difficult to achieve. This is in part due to the adverse effects that the various antihypertensive drugs have, leading patients to discontinue treatment. Among antihypertensive drugs, calcium channel blockers (CCBs) have an established efficacy of BP reduction. A common adverse effect and often cause for the poor adherence to treatment with CCBs is peripheral edema.

Dihydropyridines CCBs act by blocking calcium channels, predominantly L-type channels, thus blocking the entry of Ca2+ into cells. As a result, CCBs cause vascular smooth muscle relaxation and thus vasodilation. However, despite the same basic mechanism of action and the similar chemical structure (Figure 1), the effects of dihydropyridines CCBs are differentiated among the same class[3]. Indeed, the different pharmacokinetic profile (e.g. the elimination half-life, the extended release mechanism of some formulations and the lipophilicity of the different molecules) can lead to diverse effects of different CCBs regarding BP, heart rate and left ventricular mass.

Figure 1
Figure 1 Chemical structure of dihydropyridines calcium channel blockers.

An interesting CCB in the category of dihydropyridines is manidipine. Manidipine holds a number of traits that make it unique among dihydropyridines CCBs (Figure 2). It has a better safety profile, thus improving adherence to treatment. Moreover, its promising pleiotropic effects beyond BP lowering make it an attractive option for hypertensive subjects with concomitant CVD risk factors.

Figure 2
Figure 2 Traits of manidipine. PPARγ: Peroxisome proliferator activated receptor-γ.
SAFETY PROFILE

Among the most common adverse effects of CCBs is peripheral edema, which is dose related[4]. CCBs preferentially dilate the precapillary arterioles without a commensurate dilation of the postcapillary venules[5]. Moreover, the CCB-mediated decrease of BP leads to the triggering of the baroreflex-induced stimulation of the sympathetic nervous system[6]. In turn, this activation of the sympathetic nervous system leads to the constriction of postcapillary venules. As a result, an increase of pressure gradient in the capillary level occurs, which together with the hydrostatic pressure lead to the formation of peripheral edema. However, manidipine has shown a smaller degree of sympathetic nervous system activation. Indeed, when compared with other CCBs, manidipine is associated with lower levels of plasma norepinephrine[7]. As a result, manidipine has been shown to have a smaller incidence of peripheral edema among CCBs[8,9]. Therefore, this favorable safety profile can improve adherence to treatment and thus provide better BP control.

RENAL FUNCTION

Hypertension plays a critical role in the development and progression of renal disease[10]. Older dihydropyridines CCBs have not shown beneficial effects on renal function[11]. On the contrary, some studies have shown a decline of renal function after treatment with some CCBs[12]. There are 2 types of calcium channels: L-type and T-type. L-type calcium channels are predominantly found on afferent renal arterioles while T-type are predominantly found on efferent renal arterioles[13]. Older dihydropyridines CCBs preferentially act on L-type calcium channels. As a result, a vasodilation predominantly of the afferent glomerular arterioles is achieved with older CCBs. Therefore, no reduction in glomerular pressure is achieved and renal capillary pressure autoregulation is impaired, thus negatively affecting renal function. On the other hand, manidipine acts by blocking both L- and T-type calcium channels[14]. Consequently, a vasodilation of both afferent and efferent glomerular arterioles is achieved. As a result, manidipine improves glomerular capillary pressure and preserves renal capillary pressure autoregulation, thus favorably affecting renal function beyond BP lowering[13]. Indeed, various studies have shown the renoprotective effects and reduction of urinary albumin excretion with manidipine treatment[15,16]. Moreover, manidipine has been shown to be equally effective with enalapril (an angiotensin-converting enzyme inhibitor which has established renoprotective effects) regarding the progression of renal disease[17].

METABOLIC AND CARDIOVASCULAR EFFECTS

An able percent of hypertensive patients have additional CVD risk factors such as dyslipidemia and impaired glucose homeostasis[18]. Some antihypertensive drug categories, such as diuretics and β-blockers, have an overall unfavorable effect on lipid profile and insulin resistance[19]. On the other hand, CCBs have been shown not to significantly alter lipid levels or glucose homeostasis[20]. Manidipine has also been shown to have a neutral effect on lipids[21]. However, a beneficial effect on insulin resistance has been shown with manidipine treatment[21]. Indeed, a reduction of insulin resistance has been observed with manidipine in both non-diabetic and type 2 diabetic patients[22,23]. This favorable effect of manidipine may be linked to the drug’s capacity to partially activate the peroxisome proliferator activated receptor-γ (PPARγ)[21]. PPARγ modify the expression of numerous metabolic related genes and play a major role in glucose metabolism. The effect of manidipine to activate PPARγ is about two-thirds of that of pioglitazone, a full PPARγ activator[21]. This partial activation of PPARγ contributes to the avoidance of side effects commonly associated with thiazolidinediones treatment. Indeed, telmisartan, which is a partial PPARγ activator, has been shown to have a beneficial effect on insulin resistance without sharing the usual side effects of thiazolidinediones[24]. Moreover, an increase of adiponectin levels (which are inversely associated with the development of insulin resistance and metabolic syndrome) has been observed with manidipine[15].

Furthermore, manidipine has been shown to have an effect on cardiac function and remodeling. Indeed, a decrease of left ventricular mass[25,26] (an important CVD risk factor[27]) has been shown with manidipine treatment. Moreover, in an experimental study in rats, manidipine was associated with cardioprotective effects against heart ischemia - reperfusion injury[28]. In addition, manidipine has been shown to improve impaired coronary circulation while reducing left ventricular and vascular hypertrophy in hypertensive rats[29].

CONCLUSION

Manidipine is a unique dihydropyridine CCB with established efficacy in BP reduction. In addition, manidipine holds some unique traits which differentiate it from the rest of the CCB class. Indeed, manidipine has a better safety profile with a lower prevalence of peripheral edema. This property can lead to a better adherence to treatment and therefore a better regulation of BP. Furthermore, the drug’s ability to dilate both efferent and afferent renal arterioles contributes to the overall beneficial effects of manidipine on renal function. In addition, the capacity of manidipine to partially activate PPARγ contributes to the improvement of insulin resistance, which is often found in hypertensive subjects.

These pleiotropic effects of manidipine make it an attractive option for a more comprehensive management of hypertensive patients with the coexistence of additional CVD risk factors. Of note, it is unclear whether these pleiotropic effects of manidipine induce beneficial effects regardless of the antihypertensive effect. Moreover, promising results have been obtained when using manidipine in combination with angiotensin-converting enzyme inhibitors, such as dalapril in patients requiring a greater reduction of BP. Indeed, the manidipine/dalapril combination provided a better antihypertensive effect than monotherapy, together with a lower percentage of peripheral edema prevalence than manidipine alone[30,31].

However, these pleiotropic effects of manidipine only provide indications of possible benefits to be expected with treatment. Large clinical trials with hard clinical endpoints are needed in order to evaluate whether these pleiotropic effects are actually translated to clinical benefit.

Footnotes

Peer reviewer: Xian-Wu Cheng, MD, PhD, Associate Professor, The Department of Cardiology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466-8550, Aichiken, Japan

S- Editor Wang JL L- Editor Roemmele A E- Editor Zheng XM

References
1.  Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-223.  [PubMed]  [DOI]
2.  Reaven GM. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab. 2003;88:2399-2403.  [PubMed]  [DOI]
3.  Meredith PA, Elliott HL. Dihydropyridine calcium channel blockers: basic pharmacological similarities but fundamental therapeutic differences. J Hypertens. 2004;22:1641-1648.  [PubMed]  [DOI]
4.  Opie LH. Calcium channel antagonists. Part IV: Side effects and contraindications drug interactions and combinations. Cardiovasc Drugs Ther. 1988;2:177-189.  [PubMed]  [DOI]
5.  Gustafsson D. Microvascular mechanisms involved in calcium antagonist edema formation. J Cardiovasc Pharmacol. 1987;10 Suppl 1:S121-S131.  [PubMed]  [DOI]
6.  Fogari R. Ankle oedema and sympathetic activation. Drugs. 2005;65 Suppl 2:21-27.  [PubMed]  [DOI]
7.  Fogari R, Zoppi A, Corradi L, Preti P, Malalamani GD, Mugellini A. Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension. J Hypertens. 2000;18:1871-1875.  [PubMed]  [DOI]
8.  Richy FF, Laurent S. Efficacy and safety profiles of manidipine compared with amlodipine: a meta-analysis of head-to-head trials. Blood Press. 2010;20:54-59.  [PubMed]  [DOI]
9.  Zanchetti A, Omboni S, La Commare P, De Cesaris R, Palatini P. Efficacy, tolerability, and impact on quality of life of long-term treatment with manidipine or amlodipine in patients with essential hypertension. J Cardiovasc Pharmacol. 2001;38:642-650.  [PubMed]  [DOI]
10.  Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension. 2004;44:595-601.  [PubMed]  [DOI]
11.  Tarif N, Bakris GL. Preservation of renal function: the spectrum of effects by calcium-channel blockers. Nephrol Dial Transplant. 1997;12:2244-2250.  [PubMed]  [DOI]
12.  Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, Hammond JJ, Raffaele J, Tsalamandris C. Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Am J Kidney Dis. 2001;37:890-899.  [PubMed]  [DOI]
13.  Hayashi K, Ozawa Y, Fujiwara K, Wakino S, Kumagai H, Saruta T. Role of actions of calcium antagonists on efferent arterioles--with special references to glomerular hypertension. Am J Nephrol. 2003;23:229-244.  [PubMed]  [DOI]
14.  McKeage K, Scott LJ. Manidipine: a review of its use in the management of hypertension. Drugs. 2004;64:1923-1940.  [PubMed]  [DOI]
15.  Martínez Martín FJ. Manidipine in hypertensive patients with metabolic syndrome: the MARIMBA study. Expert Rev Cardiovasc Ther. 2009;7:863-869.  [PubMed]  [DOI]
16.  Martinez-Martin FJ, Saiz-Satjes M. Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study. Expert Rev Cardiovasc Ther. 2008;6:1347-1355.  [PubMed]  [DOI]
17.  Del Vecchio L, Pozzi M, Salvetti A, Maschio G, Fusaroli M, Rovati C, Antonucci F, Cascone C, Scanferla F, Panichi V. Efficacy and tolerability of manidipine in the treatment of hypertension in patients with non-diabetic chronic kidney disease without glomerular disease. Prospective, randomized, double-blind study of parallel groups in comparison with enalapril. J Nephrol. 2004;17:261-269.  [PubMed]  [DOI]
18.  Lind L, Berne C, Lithell H. Prevalence of insulin resistance in essential hypertension. J Hypertens. 1995;13:1457-1462.  [PubMed]  [DOI]
19.  Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens. 2006;24:3-10.  [PubMed]  [DOI]
20.  Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med. 1995;122:133-141.  [PubMed]  [DOI]
21.  Cavalieri L, Cremonesi G. Metabolic effects of manidipine. Am J Cardiovasc Drugs. 2009;9:163-176.  [PubMed]  [DOI]
22.  Iimura O, Shimamoto K, Masuda A, Higashiura K, Miyazaki Y, Hirata A, Fukuoka M, Murakami H. Effects of a calcium channel blocker, manidipine, on insulin sensitivity in essential hypertensives. J Diabetes Complications. 1995;9:215-219.  [PubMed]  [DOI]
23.  Suzuki S, Ohtomo M, Satoh Y, Kawasaki H, Hirai M, Hirai A, Hirai S, Onoda M, Hinokio Y, Akai H. Effect of manidipine and delapril on insulin sensitivity in type 2 diabetic patients with essential hypertension. Diabetes Res Clin Pract. 1996;33:43-51.  [PubMed]  [DOI]
24.  Rizos CV, Milionis HJ, Kostapanos MS, Florentin M, Kostara CE, Elisaf MS, Liberopoulos EN. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study. Clin Ther. 2010;32:492-505.  [PubMed]  [DOI]
25.  Celentano A, Crivaro M, Perticone F, Palmieri V, Oliviero M, Tammaro P, Pietropaolo I, Di Palma Esposito N, Cloro C, Cosco C. Anti-hypertensive effect of manidipine: 24 hours monitoring evaluation and Doppler-echocardiographic remarks. Blood Press Suppl. 1996;5:29-35.  [PubMed]  [DOI]
26.  Fogari R, Mugellini A, Zoppi A, Lazzari P, Destro M, Rinaldi A, Preti P. Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria. Eur J Clin Pharmacol. 2005;61:483-490.  [PubMed]  [DOI]
27.  Bauml MA, Underwood DA. Left ventricular hypertrophy: an overlooked cardiovascular risk factor. Cleve Clin J Med. 2010;77:381-387.  [PubMed]  [DOI]
28.  Masanori S, Toshihiko S, Koji H, Hidekazu H, Mitsuharu H, Takanobu A, Takeshi I, Yasuyuki B, Shigefumi S. Orally administered benidipine and manidipine prevent ischemia-reperfusion injury in the rat heart. Circ J. 2004;68:241-246.  [PubMed]  [DOI]
29.  Takeda K, Nakata T, Kuwabara T, Itoh H, Yamahara Y, Takesako T, Tanabe S, Sasaki S, Asayama J, Nakagawa M. Effect of manidipine on cardiac hypertrophy and coronary circulation in DOCA/salt hypertensive rats. Blood Press Suppl. 1992;3:48-52.  [PubMed]  [DOI]
30.  Otero ML. Manidipine-delapril combination in the management of hypertension. Vasc Health Risk Manag. 2007;3:255-263.  [PubMed]  [DOI]
31.  Fogari R, Malamani G, Zoppi A, Mugellini A, Rinaldi A, Fogari E, Perrone T. Effect on the development of ankle edema of adding delapril to manidipine in patients with mild to moderate essential hypertension: a three-way crossover study. Clin Ther. 2007;29:413-418.  [PubMed]  [DOI]